Clinical evidence questions are easy to underestimate early. A device may look technically promising, but the path to market depends on whether the intended purpose, claims, risk profile, and data package can support each other under review.
Qmed helps manufacturers build a clinical evidence strategy that is realistic, defensible, and aligned with the route to market. That means looking at the evidence requirement before the project is locked into the wrong assumptions.
What this service covers
Clinical evidence strategy can include reviewing intended purpose and claims, mapping existing clinical and non-clinical data, identifying evidence gaps, assessing where new data is likely to be needed, planning literature and data-generation activities, and connecting those decisions to the wider regulatory strategy.
It can also include defining how CER work, PMCF activities, study design, and post-market obligations fit together, so the evidence plan is not fragmented across separate documents and teams.
What a good evidence strategy should achieve
It should help a team understand what can be justified with current data, what cannot, and what the next evidence step should be. In some cases that means planning a clinical investigation. In other cases it means strengthening the data rationale, refining claims, sequencing work differently, or preparing for post-market evidence generation later.
The value is not only scientific. A strong evidence strategy also reduces the risk of building documentation around assumptions that will not hold up under scrutiny.
Typical situations
Most often, medtech innovators come to us with one or more of the following challenges:
- claims are being shaped, but the supporting evidence path is still uncertain
- existing data exists, but no one has yet tested whether it is enough for the planned route
- the team is deciding whether a study is needed, and if so what it should actually answer
- documentation work is starting before the evidence priorities have been agreed
- they want to avoid expensive rework caused by weak evidence logic later
Talk to Qmed
Tell us what claims you want to support, what data you already have, and where the evidence gaps are.